HIM
PBYI icon

Hillsdale Investment Management’s Puma Biotechnology PBYI Stock Holding History

Hillsdale Investment Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-77,800
Closed -$413K – 734
2025
Q3 		$413K Sell
77,800
-7,000
-8% -$29.7K 0.01% 436
2025
Q2 		$291K Buy
+84,800
New +$271K 0.01% 436
2023
Q4 		– Sell
-27,276
Closed -$71.7K – 624
2023
Q3 		$71.7K Sell
27,276
-775,627
-97% -$2.64M 0.01% 412
2023
Q2 		$2.83M Sell
802,903
-31,200
-4% -$97.3K 0.26% 145
2023
Q1 		$2.58M Buy
834,103
+167,897
+25% +$633K 0.22% 142
2022
Q4 		$2.82M Buy
+666,206
New +$2.3M 0.24% 142

Other funds holding PBYI

ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Hillsdale Investment Management's PBYI Position: Q4 2025 in Review

Hillsdale Investment Management sold out of Puma Biotechnology (PBYI) in Q4 2025, closing a stake of 77,800 shares — an estimated $413K sold.

Hillsdale Investment Management first reported a position in PBYI in Q4 2022 and held it in 6 quarters. The position peaked at $2.83M in Q2 2023. 151 funds tracked by Wall St. Rank hold PBYI as of Q4 2025.

  • Hillsdale Investment Management reported no remaining Puma Biotechnology position as of Q4 2025 after selling out during the quarter.
  • Hillsdale Investment Management sold 77,800 Puma Biotechnology shares in Q4 2025, an estimated $413K.
  • Hillsdale Investment Management first reported a position in Puma Biotechnology in Q4 2022 and held it in 6 quarters.
  • Hillsdale Investment Management's Puma Biotechnology position peaked at $2.83M in Q2 2023.
  • 151 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2025.

Based on Hillsdale Investment Management's 13F filing for Q4 2025, filed 10 Feb 2026.